ArticleFrontiers in oncology2026
Complex venous access in superior vena cava syndrome secondary to gray zone lymphoma, case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mediastinal gray zone lymphoma (MGZL) is a rare and biologically complex lymphoma with overlapping features of primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma. Bulky mediastinal disease frequently complicates central venous access, particularly in the presence of superior vena cava (SVC) syndrome. Reports addressing optimal vascular access strategies in this setting remain limited. Case presentation: A 41-year-old man presented with newly diagnosed MGZL and a large mediastinal mass causing clinically significant SVC obstruction. The patient required urgent initiation of intensive systemic treatment; however, standard central venous access was contraindicated due to altered thoracic venous anatomy. A tunneled femoral catheter was therefore inserted to allow treatment initiation with rituximab plus dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone (R-DA-EPOCH). The clinical course was complicated by catheter-related bloodstream infections caused by multidrug-resistant pathogens, septic shock, and pulmonary embolism, necessitating intensive care management. Following partial tumor response and anatomical decompression, duplex ultrasound-guided evaluation enabled successful implantation of a chest port via the left internal jugular vein, during which a duplicated superior vena cava was identified. Subsequent catheter-tip thrombosis was managed with low-molecular-weight heparin. Through coordinated multidisciplinary care, full-intensity R-DA-EPOCH was completed up to dose level 4, resulting in complete metabolic remission. Conclusion: This case highlights the critical importance of individualized venous access strategies in patients with mediastinal lymphoma complicated by SVC syndrome. Imaging-guided vascular assessment, multidisciplinary coordination, and adherence to international and national guidelines can enable safe delivery of curative-intent intensive chemotherapy, even in the setting of severe anatomical distortion and life-threatening complications. The case offers a visually documented, practical framework for managing venous access in complex anatomical conditions associated with superior vena cava syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.